Anupam Rasayan India Releases Q2 & H1 FY26 Earnings Call Transcript with Stellar Revenue Growth

Anupam Rasayan India Limited has submitted the transcript of its Earnings Call for the unaudited financial results (Standalone and Consolidated) for the quarter and half year ended September 30, 2025. The company reported a strong financial performance: * Q2 FY26 Consolidated Financial Highlights: * Revenue from operations: ₹731.4 crore, a 148.8% year-on-year increase and 50.5% sequentially. * EBITDA (including other income): ₹143.58 crore, up 74.4% year-on-year, with an EBITDA margin of 19.5%. * Profit After Tax (PAT): ₹57.15 crore, up 86.6% year-on-year, with a PAT margin of 7.8%. * H1 FY26 Consolidated Financial Highlights: * Revenue from operations: ₹1,217.22 crore, a 122.1% year-on-year increase. * EBITDA (including other income): ₹272.78 crore, up 92.6% year-on-year, with an EBITDA margin of 22.2%. * Profit After Tax (PAT): ₹105.61 crore, up 146.6% year-on-year, with a PAT margin of 8.6%.

Management Commentary and Outlook: * Managing Director Mr. Anand Desai stated that Q2 FY26 was one of the best quarters, with the company surpassing total FY25 revenue within the first six months of FY26. * EBITDA margins were slightly subdued due to dispatches from older inventory but are expected to normalize from Q3 onwards to around 25%. * The US market remains a key growth driver, with 58% of total revenue from exports, largely unaffected by US tariffs. * The order book stands healthy at approximately ₹14,646 crore, spread over 5-7 years, expected to contribute around ₹450 crore in revenue during FY26. * One new molecule was successfully launched in the Pharma segment in Q2 FY26. * Life Science Related Specialty Chemicals contributed 84% of H1 FY26 revenue, with the Pharma segment growing 201% year-on-year. Performance Materials contributed 16% of revenue, growing 306% year-on-year. * Working capital days improved significantly from 409 days in FY25 to 247 days in H1 FY26, with a target to reduce to 200 days in the near term. * Net debt reduced to ₹730 crore at the consolidated level after utilizing ₹175 crore from warrant proceeds received in July 2025. * The company expects over 50% growth in FY26, driven by recovery in agrochemicals and growth in polymer and pharma segments. * Management is actively exploring inorganic opportunities to expand its presence in the polymer sector. * Promoter shares were pledged to raise money for participation in the preferential allotment.